Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses

开发口服、脑/眼穿透性第二代 TTR 稳定剂,用于治疗运甲状腺素蛋白淀粉样变性

基本信息

  • 批准号:
    10019419
  • 负责人:
  • 金额:
    $ 21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-30 至 2021-07-31
  • 项目状态:
    已结题

项目摘要

The TTR Amyloidoses (ATTR) are rare, progressive, ultimately fatal diseases that compromise the function of multiple organs, causing a wide range of debilitating clinical symptoms. ATTR is caused by the dissociation of the tetrameric transthyretin (TTR) protein, leading to misfolding and aggregation of the released monomers with toxic oligomer formation and subsequent tissue deposition as physiologically insoluble amyloid fibrils (amyloidogenesis). While circulating TTR is synthesized predominantly in the liver, TTR in the eye and the brain is made locally by retinal pigment and choroid plexus epithelial cells, respectively. Autosomal dominant disease is caused by one of 123 germ-line destabilizing TTR mutations that exhibit a spectrum of disease phenotypes including polyneuropathy, cardiomyopathy, ocular pathology, focal central neurologic episodes and dementia. Sporadic aging-associated Senile Systemic Amyloidosis (SSA), in which wild type TTR is the amyloid precursor, displays a primarily cardiac and carpal tunnel syndrome phenotype. Current treatment options for ATTR are based on 1) eliminating production of the disease-accelerating TTR mutants through TTR gene therapy mediated by liver transplantation (LT) or mRNA lowering agents, such as patisiran and inotersen; and 2) preventing circulating TTR dissociation, which is rate-limiting for aggregation with the small molecule TTR kinetic stabilizer, tafamidis, which selectively binds and stabilizes native tetrameric TTR, thereby effectively halting disease progression. Tafamidis has received regulatory agency approval in ~40 countries for the treatment of Familial Amyloidotic Polyneuropathy caused by TTR mutations; in a recent phase III study, tafamidis also significantly reduced all-cause mortality and cardiac hospitalizations in patients with SSA. Despite achieving significant increases in lifespan and health span, LT, gene knockdown, and tafamidis do not prevent the well documented onset or progression of ocular and central nervous system (CNS) symptoms related to locally synthesized TTR (systemically administered tafamidis does not attain therapeutic concentrations in these tissues). Since kinetic stabilizers such as tafamidis dramatically slows peripheral degenerative disease progression, it is likely that developing a kinetic stabilizer with effective levels in the brain and eyes of ATTR patients will meet an urgent medical need. To achieve that goal, we will conduct a full-fledged drug discovery program including lead identification, SAR guided optimization, in vitro and in vivo pharmacokinetic studies (see preliminary data) to generate a TTR kinetic stabilizer achieving sufficient levels in the eye and/or CNS to slow disease progression. Tafamidis was invented and developed by members of our team (Kelly and Labaudinière), de-risking the 2nd generation kinetic stabilizer strategy. The effort proposed here will be combined with our proprietary early diagnostic and response-to-therapy biomarker strategies, facilitating the generation of a drug candidate ready for pre-clinical, IND-enabling studies.
TTR淀粉样变性(ATTR)是一种罕见的、进行性的、最终致命的疾病,它损害多个器官的功能,导致广泛的衰弱临床症状。ATTR是由四聚体转甲状腺素(TTR)蛋白解离引起的,导致释放的单体错误折叠和聚集,形成有毒低聚物,随后组织沉积为生理上不可溶的淀粉样纤维(淀粉样蛋白形成)。循环中的TTR主要在肝脏中合成,而眼睛和大脑中的TTR分别由视网膜色素和脉络丛上皮细胞局部合成。常染色体显性遗传病是由123种不稳定的TTR突变之一引起的,这些突变表现出一系列疾病表型,包括多发性神经病、心肌病、眼部病理、局灶性中枢神经发作和痴呆。散发性衰老相关性老年性淀粉样变性(SSA)以野生型TTR为淀粉样前体,主要表现为心脏和腕管综合征表型。目前对ATTR的治疗选择基于1)通过肝移植(LT)或mRNA降低剂(如Patisiran和inotersen)介导的TTR基因疗法消除加速疾病的TTR突变体的产生;以及2)防止循环TTR解离,这对小分子TTR动力学稳定剂他法米迪的聚集具有限速作用,他法米迪选择性地结合和稳定天然四聚体TTR,从而有效地阻止疾病的进展。他法米迪已经在大约40个国家和地区获得了监管机构的批准,用于治疗由TTR突变引起的家族性淀粉样变性多发性神经病;在最近的一项第三阶段研究中,他法米迪还显著降低了SSA患者的全因死亡率和心脏住院率。尽管在寿命和健康寿命方面取得了显著的延长,LT、基因敲除和他法米迪并不能阻止与局部合成的TTR相关的眼睛和中枢神经系统(CNS)症状的发生或发展(系统地给药他法米迪在这些组织中不能达到治疗浓度)。由于像他法米迪这样的运动稳定剂可以显著减缓外周退行性疾病的进展,因此开发一种在ATTR患者的大脑和眼睛中具有有效水平的运动稳定剂很可能满足紧急的医疗需求。为了实现这一目标,我们将进行一项成熟的药物发现计划,包括铅识别、合成孔径雷达引导优化、体外和体内药代动力学研究(见初步数据),以产生在眼睛和/或中枢神经系统达到足够水平以减缓疾病进展的TTR动力学稳定剂。他法米迪是由我们团队的成员(Kelly和Labaudinière)发明和开发的,降低了第二代动力稳定器策略的风险。这里提出的努力将与我们专有的早期诊断和治疗反应生物标记物战略相结合,促进产生一种准备用于临床前、使能IND的研究的候选药物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard Labaudiniere其他文献

Richard Labaudiniere的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 21万
  • 项目类别:
Parkinson's disease and aging affect neural activation during continuous gait alterations to the split-belt treadmill: An [18F] FDG PET Study.
帕金森病和衰老会影响分体带跑步机连续步态改变期间的神经激活:[18F] FDG PET 研究。
  • 批准号:
    400097
  • 财政年份:
    2019
  • 资助金额:
    $ 21万
  • 项目类别:
The elucidation of the mechanism by which intestinal epithelial cells affect impaired glucose tolerance during aging
阐明衰老过程中肠上皮细胞影响糖耐量受损的机制
  • 批准号:
    19K09017
  • 财政年份:
    2019
  • 资助金额:
    $ 21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Does aging of osteocytes adversely affect bone metabolism?
骨细胞老化会对骨代谢产生不利影响吗?
  • 批准号:
    18K09531
  • 财政年份:
    2018
  • 资助金额:
    $ 21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Links between affect, executive function, and prefrontal structure in aging: A longitudinal analysis
衰老过程中情感、执行功能和前额叶结构之间的联系:纵向分析
  • 批准号:
    9766994
  • 财政年份:
    2018
  • 资助金额:
    $ 21万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 21万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 21万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 21万
  • 项目类别:
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
衰老过程中抑郁症的实验模型:失眠、炎症和影响机制
  • 批准号:
    9925164
  • 财政年份:
    2016
  • 资助金额:
    $ 21万
  • 项目类别:
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
衰老过程中抑郁症的实验模型:失眠、炎症和影响机制
  • 批准号:
    9345997
  • 财政年份:
    2016
  • 资助金额:
    $ 21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了